Literature DB >> 12145779

Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration.

Dick C Chan1, Gerald F Watts, Trevor G Redgrave, Trevor A Mori, P Hugh R Barrett.   

Abstract

Obesity is strongly associated with dyslipidemia, which may account for the associated increased risk of atherosclerosis and coronary disease. We aimed to test the hypothesis that kinetics of hepatic apolipoprotein B-100 (apoB) metabolism are disturbed in men with visceral obesity and to examine whether these kinetic defects are associated with elevated plasma concentration of apolipoprotein C-III (apoC-III). Very-low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), and low-density lipoprotein (LDL) apoB kinetics were measured in 48 viscerally obese men and 10 age-matched normolipidemic lean men using an intravenous bolus injection of d(3)-leucine. ApoB isotopic enrichment was measured using gas chromatography-mass spectrometry (GCMS). Kinetic parameters were derived using a multicompartmental model (Simulation, Analysis, and Modeling Software II [SAAM-II]). Compared with controls, obese subjects had significantly elevated plasma concentrations of plasma triglycerides, cholesterol, LDL-cholesterol, VLDL-apoB, IDL-apoB, LDL-apoB, apoC-III, insulin, and lathosterol (P <.01). VLDL-apoB secretion rate was significantly higher (P =.034) in obese than control subjects; the fractional catabolic rates (FCRs) of IDL-apoB and LDL-apoB (P <.01) and percent conversion of VLDL-apoB to LDL-apoB (P <.02) were also significantly lower in obese subjects. However, the decreased VLDL-apoB FCR was not significantly different from the lean group. In the obese group, plasma concentration of apoC-III was significantly and positively associated with VLDL-apoB secretion rate and inversely with VLDL-apoB FCR and percent conversion of VLDL to LDL. In multiple regression analysis, plasma apoC-III concentration was independently and significantly correlated with the secretion rate of VLDL-apoB (regression coefficient [SE] 0.511 [0.03], P =.001) and with the percent conversion of VLDL-apoB to LDL-apoB (-0.408 [0.01], P =.004). Our findings suggest that plasma lipid and lipoprotein abnormalities in visceral obesity may be due to a combination of overproduction of VLDL-apoB particles and decreased catabolism of apoB containing particles. Elevated plasma apoC-III concentration is also a feature of dyslipidemia in obesity that contributes to the kinetic defects in apoB metabolism. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12145779     DOI: 10.1053/meta.2002.33339

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  27 in total

Review 1.  Studying apolipoprotein turnover with stable isotope tracers: correct analysis is by modeling enrichments.

Authors:  Rajasekhar Ramakrishnan
Journal:  J Lipid Res       Date:  2006-09-01       Impact factor: 5.922

2.  A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels.

Authors:  Sumeet A Khetarpal; Xuemei Zeng; John S Millar; Cecilia Vitali; Amritha Varshini Hanasoge Somasundara; Paolo Zanoni; James A Landro; Nicole Barucci; William J Zavadoski; Zhiyuan Sun; Hans de Haard; Ildikó V Toth; Gina M Peloso; Pradeep Natarajan; Marina Cuchel; Sissel Lund-Katz; Michael C Phillips; Alan R Tall; Sekar Kathiresan; Paul DaSilva-Jardine; Nathan A Yates; Daniel J Rader
Journal:  Nat Med       Date:  2017-08-21       Impact factor: 53.440

3.  Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes.

Authors:  Anne Hiukka; Jamila Fruchart-Najib; Eeva Leinonen; Hannele Hilden; Jean-Charles Fruchart; Marja-Riitta Taskinen
Journal:  Diabetologia       Date:  2005-04-30       Impact factor: 10.122

4.  Deficiency in Nrf2 transcription factor decreases adipose tissue mass and hepatic lipid accumulation in leptin-deficient mice.

Authors:  Jialin Xu; Ajay C Donepudi; Vijay R More; Supriya R Kulkarni; Liya Li; Liangran Guo; Bingfang Yan; Tapan Chatterjee; Neal Weintraub; Angela L Slitt
Journal:  Obesity (Silver Spring)       Date:  2014-11-29       Impact factor: 5.002

5.  Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus.

Authors:  Kazunori Nagashima; Carlos Lopez; Daniel Donovan; Colleen Ngai; Nelson Fontanez; André Bensadoun; Jamila Fruchart-Najib; Steve Holleran; Jeffrey S Cohn; Rajasekhar Ramakrishnan; Henry N Ginsberg
Journal:  J Clin Invest       Date:  2005-04-01       Impact factor: 14.808

6.  Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome.

Authors:  Dick C Chan; Gerald F Watts; Esther M M Ooi; Juying Ji; Anthony G Johnson; P Hugh R Barrett
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-06-19       Impact factor: 8.311

7.  Inhibition of apoB secretion from HepG2 cells by insulin is amplified by naringenin, independent of the insulin receptor.

Authors:  Emma M Allister; Erin E Mulvihill; P Hugh R Barrett; Jane Y Edwards; Lindsey P Carter; Murray W Huff
Journal:  J Lipid Res       Date:  2008-06-27       Impact factor: 5.922

8.  Mathematical modelling of competitive LDL/VLDL binding and uptake by hepatocytes.

Authors:  T Pearson; J A D Wattis; B O'Malley; L Pickersgill; H Blackburn; K G Jackson; H M Byrne
Journal:  J Math Biol       Date:  2008-08-14       Impact factor: 2.259

9.  Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism.

Authors:  Dick C Chan; Minh N Nguyen; Gerald F Watts; P Hugh R Barrett
Journal:  J Clin Endocrinol Metab       Date:  2007-11-13       Impact factor: 5.958

Review 10.  Fatty liver, insulin resistance, and dyslipidemia.

Authors:  Martin Adiels; Marja-Riitta Taskinen; Jan Borén
Journal:  Curr Diab Rep       Date:  2008-02       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.